Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Carpal Tunnel Syndrome in Patients Who Underwent Pacemaker Implantation and Relation to Amyloidosis, Heart Failure, and Mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  • DAPA-HF Investigators and Committees
View graph of relations

OBJECTIVE: The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial.

RESEARCH DESIGN AND METHODS: The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg daily or placebo. In this exploratory analysis, surveillance for new-onset diabetes was accomplished through periodic HbA1c testing as part of the study protocol and comparison between the treatment groups assessed through a Cox proportional hazards model.

RESULTS: At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a placebo-adjusted change in the dapagliflozin group of -0.04%. Over a median follow-up of 18 months, diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (hazard ratio 0.68, 95% CI 0.50-0.94; P = 0.019). More than 95% of the participants who developed T2D had prediabetes at baseline (HbA1c 5.7-6.4%). Participants who developed diabetes in DAPA-HF had a higher subsequent mortality than those who did not.

CONCLUSIONS: In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.

Original languageEnglish
JournalDiabetes Care
Volume44
Issue number2
Pages (from-to)586-594
Number of pages9
ISSN1935-5548
DOIs
Publication statusPublished - Feb 2021

Bibliographical note

© 2020 by the American Diabetes Association.

    Research areas

  • Benzhydryl Compounds/therapeutic use, Diabetes Mellitus, Type 2/complications, Glucosides, Heart Failure/drug therapy, Humans, Incidence, Stroke Volume

ID: 72739707